Mexico City, 25 July 2018: Mundipharma has expanded its ophthalmology portfolio in Latin America by agreeing a new commercial partnership with NTC – an Italian pharmaceutical company with deep experience in research and development – for exclusive rights to license and distribute a range of ophthalmic medicines across the region...

The company anticipates the next opening of a branch in Spain, with a broad portfolio of quality products. 

CPhI Worldwide, 9 - 11 October 2018.
See you in Madrid. #cphi.com

In Milan, on May 12, NTC Pharma organised Leader7 Investigators’ Meeting with 90 ophthalmologists representing 57 Italian centers, OPIS Group team and NTC people involved in this clinical research project, one of the widest multicentre clinical studies conducted in Europe in Ophthalmology. NTC is strongly committed in the fight against antibiotic resistance as demonstrated by this study and other initiatives that are building the path of NTC to the Next Level.